Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 58
- Emerging
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsResearch Summary
Analyzed using Evidence Intelligence™
Mazdutide improves metabolic outcomes in adolescents with obesity and diabetes
Last updated July 4, 2026
Key finding
Weight decreased by 16.8 kg.
The study evaluated the effects of Mazdutide on an adolescent with obesity-related type 2 diabetes, showing significant improvements in metabolic parameters.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
Non-randomized CT
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save this study and add notes to your research library.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
The study evaluated the effects of Mazdutide on an adolescent with obesity-related type 2 diabetes, showing significant improvements in metabolic parameters.
Clinical relevance
These findings are clinically significant as they suggest that Mazdutide may be an effective treatment option for adolescents struggling with obesity-related type 2 diabetes. The substantial reductions in weight, blood sugar, and lipid levels indicate potential for improved long-term health outcomes, which is crucial given the rising prevalence of diabetes in younger populations.
Keep in mind
Non-randomized study design limits generalizability. Only one participant was studied, affecting the robustness of findings. Lack of long-term follow-up data on the sustainability of results.
Published in
Journal Reference
Publication details and source links for this paper.
Wenfei C, Zilong C, Puyu L, et al. Mazdutide Exhibits Robust Metabolic Efficacy in an Adolescent with Obesity-Related Type 2 Diabetes. Frontiers in Endocrinology. 2025;16:1654506. doi:10.3389/fendo.2025.1654506
Main Effects
Body weight decreased by 16.8 kg, representing an 18.89% reduction in BMI.
HbA1c levels fell from 9.60% to 7.50%.
Triglycerides decreased from 1.84 mmol/L to 0.57 mmol/L.
Resolution of hepatic steatosis was confirmed by ultrasound by week 14.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Mazdutide and BMI, Body weight, HbA1c, and 6 more.
This study contributes evidence to
Primary intervention
Mazdutide
Primary outcomes
- BMI
- Body weight
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
9
Evidence pairs
9
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
9
Evidence pairs
322
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 9 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 58
- Emerging
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 58
- Emerging
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsEvidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- 58
- Emerging
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 58
- Emerging
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsResolution of Hepatic Steatosis
Mazdutide → Resolution of Hepatic Steatosis
Mazdutide → Resolution of Hepatic Steatosis
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 58
- Emerging
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 58
- Emerging
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 58
- Emerging
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 58
- Emerging
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsUnlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Body weight reduction of 16.8 kg observed.
- HbA1c decreased by 21.88%, indicating better blood sugar control.
- Triglycerides fell by 69.02%, improving lipid profile.
Who this applies to
- Adolescents aged 12-18 with obesity-related type 2 diabetes.
- Individuals with high BMI and metabolic syndrome.
Keep in Mind
- Results are based on a single case study, which may not reflect broader population effects.
- The study did not include a control group for comparison.
- Further research is needed to confirm findings in larger, diverse populations.
Between the Lines
- Non-randomized study design limits generalizability.
- Only one participant was studied, affecting the robustness of findings.
- Lack of long-term follow-up data on the sustainability of results.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Mass Index, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceGLP-1 Receptor Agonists → Body Mass Index
Medications
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 58
- Emerging
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Detailed evidenceGLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 58
- Emerging
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Detailed evidenceEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 58
- Emerging
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Adipokine and Angiogenic Markers Evidence Hub
All studies measuring Adipokine and Angiogenic Markers
1 studies
outcome_hubMeasures Adipokine and Angiogenic Markers as a key outcome.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
1 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
1 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Mazdutide and BMI
Intervention: MazdutideOutcome: BMI
1 results
All studies on Mazdutide and Body weight
Intervention: MazdutideOutcome: Body weight
1 results
All studies on Mazdutide
Intervention: Mazdutide
1 results
All studies measuring BMI
Outcome: BMI
1 results
All studies measuring Body weight
Outcome: Body weight
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 58.5 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 25 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 58.5 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 25 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body mass index?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 58.5 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect hypoglycemia?
Strong Evidence
GLP-1 Receptor Agonists may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Hypoglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 58.5 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesMediterranean ketogenic eating matched VLCKD for weight loss over 3 monthsNatural products may improve glycemic control in type 2 diabetesDietary supplements may lower diabetes risk in prediabetesGLP-1 agonists reduce heart fat thickness in diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.